Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Sells $244,000.00 in Stock

Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Director Richard K. Prins sold 5,000 shares of Amphastar Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $48.80, for a total transaction of $244,000.00. Following the completion of the transaction, the director now directly owns 31,471 shares of the company’s stock, valued at $1,535,784.80. This trade represents a 13.71 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Amphastar Pharmaceuticals Trading Down 1.0 %

Amphastar Pharmaceuticals stock opened at $44.61 on Friday. The company has a quick ratio of 2.61, a current ratio of 3.43 and a debt-to-equity ratio of 0.82. The firm has a 50-day moving average price of $48.40 and a two-hundred day moving average price of $44.37. The firm has a market capitalization of $2.14 billion, a price-to-earnings ratio of 14.87, a PEG ratio of 0.88 and a beta of 0.82. Amphastar Pharmaceuticals, Inc. has a 52-week low of $36.56 and a 52-week high of $65.92.

Institutional Trading of Amphastar Pharmaceuticals

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Silvercrest Asset Management Group LLC raised its position in shares of Amphastar Pharmaceuticals by 35.1% during the 1st quarter. Silvercrest Asset Management Group LLC now owns 112,428 shares of the company’s stock worth $4,937,000 after buying an additional 29,182 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 3rd quarter worth about $11,070,000. Intech Investment Management LLC bought a new stake in shares of Amphastar Pharmaceuticals during the 2nd quarter worth about $426,000. Granite Investment Partners LLC raised its position in shares of Amphastar Pharmaceuticals by 12.7% during the 2nd quarter. Granite Investment Partners LLC now owns 397,514 shares of the company’s stock worth $15,901,000 after buying an additional 44,744 shares in the last quarter. Finally, 1620 Investment Advisors Inc. bought a new stake in shares of Amphastar Pharmaceuticals in the 2nd quarter worth approximately $93,000. 65.09% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have recently commented on AMPH shares. Needham & Company LLC reaffirmed a “hold” rating on shares of Amphastar Pharmaceuticals in a report on Thursday, August 8th. Piper Sandler decreased their price target on shares of Amphastar Pharmaceuticals from $71.00 to $66.00 and set an “overweight” rating for the company in a report on Thursday, August 8th. Finally, StockNews.com lowered shares of Amphastar Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, November 1st. Three equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, Amphastar Pharmaceuticals presently has an average rating of “Hold” and an average target price of $63.00.

Amphastar Pharmaceuticals Company Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.